Lumara Health 女性醫藥 分拆 轉手 (AMAG/Perrigo)

Lumara Health to Sell Assets to AMAG, Perrigo for $757 Million AMAG Pharmaceuticals Sees Deal Immediately Adding to Earnings  By CHELSEY DULANEY CONNECT Sept. 29, 2014 8:19 a.m. ET Closely held drug maker Lumara Health Inc. agreed to sell its maternal health business and women's health-care assets in separate deals to AMAG Pharmaceuticals Inc. AMAG -0.66%  and Perrigo Co. PRGO +1.53%  for about $757 million. AMAG will buy the maternal health business for $675 million in cash and stock to help diversify its drug portfolio. Lumara's flagship drug is Makena, which is used to reduce the risk of preterm birth in pregnant women. Makena posted more than $130 million in sales in the 12 months ended Aug. 31, AMAG said. In 2011, the U.S. Food and Drug Administration gave Makena seven-year orphan drug exclusivity. The deal, which is made up of $600 million in cash and $75 million in stock, is expected to immediately add to AMAG's per-share earnings and result in at least $20 million in cost synergies a year. Lumara could receive an additional $350 million if certain sales milestones are achieved. Shares of AMAG climbed more than 12% in premarket trading. AMAG, which markets Feraheme, an IV drug used to treat chronic kidney disease, and MuGard oral wound rinse, has posted heavy losses in recent years. In July, the company projected a deeper-than-expected loss for the fiscal year. Lumara will function as a separate business within AMAG, reporting directly to AMAG's chief executive, William Heiden. Meanwhile, Lumara will sell its women's health-care assets, which include a vaginal cream and a skin spray, for $82 million to drug and supplements maker Perrigo. The deals are expected to close in the fourth quarter.

Lumara Health Inc. (Lumara), formerly K-V Pharmaceutical Company, is a specialty pharmaceutical company. It develops and commercializes branded pharmaceuticals in various dosage forms such as solids, semi-solids and liquids. The company focuses its products in the women healthcare area. It operates through two business divisions, namely, Maternal Health and Women's Healthcare. Maternal Health Division focuses on addressing preterm birth and Women's Healthcare Division focuses on women's health with products for menopausal symptoms and vaginal infections. The product portfolio of the company includes anti-infectives and estrogen therapy products that are marketed under Evamist, Clindesse, Gynazole-1 and Makena brands. The company markets its products through its subsidiary Ther-Rx Corporation. Lumara is headquartered in Missouri, the US.